Martin Bolli, PhD, Founder
Martin Bolli knows his way around molecules – and not just a few. With a PhD from ETH Zürich and postdoc stints stretching from Cambridge to sunny San Diego, he has seen more lab benches than most of us have coffee mugs. Over 25 years in drug discovery at Actelion and Idorsia, he helped bring three drugs to market. With over 100 publications and patents to his name, he topped it off with the prestigious KGF-SCS Industrial Investigator Award in 2016. In short: if drug discovery were a sport, Martin would have quite a few medals hanging on the wall.
Key Publications
Bolli et al. Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases
J. Med. Chem. 2024, 67, 4, 2397–2424 Link to ACS
Bolli et al. The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist J. Med. Chem. 2012 ,55,7849-7861 Link to ACS
Bolli et al. 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists (Ponesimod) J. Med. Chem. 2010, 53, 4198-4211 Link to ACS
Bolli et al. Novel S1P1 receptor agonists – Part 5: From amino-to alkoxy-pyridines (cenerimod) Eur. J. Med. Chem. 2016, 115, 326-341 Link to Science Direct